In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum

D. A. Conrad, R. K. Scribner, A. H. Weber, M. I. Marks

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

The antibacterial activity of BMY-28142, a new aminothiazole cephalosporin, was measured by standardized broth microdilution and agar dilution methods against 450 gram-positive and gram-negative bacteria isolated from pediatric infections, including acute pulmonary exacerbations of cystic fibrosis. BMY-28142 activity was compared with that of aminoglycosides, β-lactams, chloramphenicol, trimethoprim-sulfamethoxazole, vancomycin, and clindamycin. The activity of BMY-28142 in combination with other antimicrobial agents against Pseudomonas aeruginosa was also determined. Furthermore, the effects of inoculum and pH on BMY-28142 activity were evaluated. BMY-21842 was active against most of the gram-positive and gram-negative isolates, with the exception of methicillin-resistant Staphylococcus aureus and Pseudomonas cepacia. The combination of BMY-28142 with tobramycin was often synergistic, and combinations of BMY-28142 with either polymyxin B or imipenem were usually antagonistic. BMY-28142 antibacterial activity could be adversely affected at extremes of medium pH and by high inoculum densities.

Original languageEnglish (US)
Pages (from-to)58-63
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume28
Issue number1
DOIs
StatePublished - 1985

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum'. Together they form a unique fingerprint.

Cite this